bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) has been researched along with Colorectal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, R; Feig, B; Hu, W; Khokhar, AR; Kumagai, S; Lee, SJ; Maclean, DS; Mansfield, P; Siddik, ZH; Verschraegen, CF | 1 |
| Dragovich, T; Hoos, A; Kurtin, S; Mendelson, D; Richardson, K; Von Hoff, D | 1 |
2 trial(s) available for bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) and Colorectal Neoplasms
| Article | Year |
|---|---|
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Area Under Curve; Ascites; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; Endometrial Stromal Tumors; Female; Humans; Injections, Intraperitoneal; Liposomes; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Peritoneum; Radionuclide Imaging; Technetium; Tissue Distribution | 2003 |
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Humans; Hyperbilirubinemia; Liposomes; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Peripheral Nervous System Diseases; Treatment Outcome; Vomiting | 2006 |